Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi.
about
Intestinal invasion and disseminated disease associated with Penicillium chrysogenumNovel perspectives on mucormycosis: pathophysiology, presentation, and management.Recent advances in diagnosis and management of Mycotic KeratitisPosaconazole: an oral triazole with an extended spectrum of activityEpidemiology of invasive candidiasis: a persistent public health problemClinical, morphological, and molecular characterization of Penicillium canis sp. nov., isolated from a dog with osteomyelitis.Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data.Successful treatment of a case with rhino-orbital-cerebral mucormycosis by the combination of neurosurgical intervention and the sequential use of amphotericin B and posaconazole.Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus.Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.A five-year survey of dematiaceous fungi in a tropical hospital reveals potential opportunistic speciesIn vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methodsSteady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational sMultiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, andPharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infectionEvaluation and treatment of chronic meningitis.Rapid susceptibility testing of medically important zygomycetes by XTT assay.Identification of novel genes conferring altered azole susceptibility in Aspergillus fumigatus.Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers.International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003).Voriconazole-Resistant Penicillium oxalicum: An Emerging Pathogen in Immunocompromised Hosts.Epidemiology and treatment approaches in management of invasive fungal infectionsVoriconazole in the management of nosocomial invasive fungal infections.Human Fungal Pathogens of Mucorales and Entomophthorales.How to treat severe infections in critically ill neutropenic patients?PCR based identification and discrimination of agents of mucormycosis and aspergillosis in paraffin wax embedded tissue.Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.Expression of immunomodulatory genes in human monocytes induced by voriconazole in the presence of Aspergillus fumigatus.Differences in efficacy and cytokine profiles following echinocandin or liposomal amphotericin B monotherapy or combination therapy for murine pulmonary or systemic Aspergillus flavus infectionsChanging strategies for the management of invasive fungal infections.In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection.Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.Combination treatment of invasive fungal infections.Fusarium peritonitis concomitant to kidney transplantation successfully managed with voriconazole: case report and review of the literature.New agents for the prevention of opportunistic infections in haematopoietic stem cell transplant recipients.Posaconazole: clinical pharmacology and potential for management of fungal infections.Safety and potential of drug interactions of caspofungin and voriconazole in multimorbid patients.Management of intracranial fungal infections in patients with haematological malignancies.A review of clinical experience with newer antifungals in children
P2860
Q21245799-BAB28699-DFCF-439A-B02E-3750F1C12CB1Q24530554-F642167E-FE58-4032-B343-DC3097378E52Q26744422-E0ECA57F-C1AD-48A7-8ABB-CDC884B0B2EEQ28291282-8627A006-FE06-41E8-87DD-4F5F1128CEC9Q29616758-B2C5B635-D42C-4D7C-9933-5828F9EE66B5Q30583695-5ED0BE68-C2FC-4258-8B3A-6014EFDD9603Q30873926-B4FD3C8A-8AD6-4F29-8DB9-30CB668B5412Q33633913-85EF53B6-56F2-45AD-AD16-98D2D88C50CDQ33857685-258BDDA8-F4F9-4561-A587-BF511487E42EQ33938068-6E7FCCFA-3CEC-4F40-8232-6BBF1EE91A00Q34011074-7DE89442-EBA4-4B72-968B-D5F06D0C877AQ34041745-0122C466-FC53-4720-889B-407697266F53Q34108650-2C1545E8-B9D6-4BEE-8178-C8DE71C4FD20Q34288593-527D5F43-4096-4A7B-9C51-2340F271C0D0Q34309603-EC29A313-00EA-4737-88D0-F3E22311C53CQ34352014-8F3488FC-13B0-4021-A025-A27B0FC5DAE1Q34418500-CEA69572-649B-46DD-9575-C9BF99DBF507Q34430832-1D660848-141A-4D5A-A372-BC81DB0C96E1Q34452089-028379D0-8DCE-4276-9B78-F6908B671E72Q34648517-215FDC6F-486F-4564-9348-F7397F900AEBQ34680831-09EFCD34-1948-45D5-B0A5-AB48CDA62652Q34802129-07ECC6AC-2A95-434D-AA72-1DF00E214547Q35089772-CF63AA5C-25FA-4036-8F1B-A5C7D92B3F84Q35166823-0489565A-27A2-4241-91C7-D381E11217F4Q35245238-F985AF26-6BE5-4244-9C34-1D49341C18A3Q35457899-E03D31E5-FF9C-4A3F-BA98-CABA1895A8A8Q35588822-E55EBF83-9C1A-41C1-9ABA-F33BB827E2C0Q35647678-DD5BAB74-AFEB-4DC9-815F-0650A9673CC7Q35647730-0B785EB8-5160-4AE2-B8C3-E73B5E2AA379Q35666612-E5EBD540-D123-492F-8FF6-6C8F68A7AEDCQ35678997-6C427125-E6CB-49F4-A1BE-E8369D62AEBBQ35870651-D5DF2A57-1197-41BB-83DE-094407E9EFA5Q35912243-82DEC493-6AF8-4D7C-9B0D-41229704B77DQ36011378-53A9B5E4-AFB3-464C-93B3-994F100E481AQ36093394-FCADCF98-9414-418E-9603-5DD07AA9AB18Q36222041-FDCF20BE-0483-45B4-9EF0-CF1309A580F9Q36233491-C73C059B-6420-4FE2-BCB3-D1D07304FB26Q36271648-FE01B17D-150E-416D-8BD2-28BAB32CA26FQ36286439-1D318EB3-76AD-4037-BB2D-415B63A7BF1AQ36290698-94FA946B-2E4A-4DC1-99EB-C4CB09491152
P2860
Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Activities of caspofungin, itr ...... isolates of filamentous fungi.
@ast
Activities of caspofungin, itr ...... isolates of filamentous fungi.
@en
type
label
Activities of caspofungin, itr ...... isolates of filamentous fungi.
@ast
Activities of caspofungin, itr ...... isolates of filamentous fungi.
@en
prefLabel
Activities of caspofungin, itr ...... isolates of filamentous fungi.
@ast
Activities of caspofungin, itr ...... isolates of filamentous fungi.
@en
P2093
P2860
P1476
Activities of caspofungin, itr ...... isolates of filamentous fungi.
@en
P2093
D J Diekema
M A Pfaller
R J Hollis
S A Messer
P2860
P304
P356
10.1128/JCM.41.8.3623-3626.2003
P407
P577
2003-08-01T00:00:00Z